130 related articles for article (PubMed ID: 15669185)
1. U0126 prevents ERK pathway phosphorylation and interleukin-1beta mRNA production after cerebral ischemia.
Wang ZQ; Chen XC; Yang GY; Zhou LF
Chin Med Sci J; 2004 Dec; 19(4):270-5. PubMed ID: 15669185
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of MEK/ERK 1/2 pathway reduces pro-inflammatory cytokine interleukin-1 expression in focal cerebral ischemia.
Wang ZQ; Wu DC; Huang FP; Yang GY
Brain Res; 2004 Jan; 996(1):55-66. PubMed ID: 14670631
[TBL] [Abstract][Full Text] [Related]
3. Picroside II Inhibits the MEK-ERK1/2-COX2 Signal Pathway to Prevent Cerebral Ischemic Injury in Rats.
Wang T; Zhai L; Zhang H; Zhao L; Guo Y
J Mol Neurosci; 2015 Nov; 57(3):335-51. PubMed ID: 26240040
[TBL] [Abstract][Full Text] [Related]
4. Effects of extracellular signal-regulated kinase (ERK) on focal cerebral ischemia.
Wang Z; Chen X; Zhou L; Wu D; Che X; Yang G
Chin Med J (Engl); 2003 Oct; 116(10):1497-503. PubMed ID: 14570609
[TBL] [Abstract][Full Text] [Related]
5. Enhanced expressions of microvascular smooth muscle receptors after focal cerebral ischemia occur via the MAPK MEK/ERK pathway.
Maddahi A; Edvinsson L
BMC Neurosci; 2008 Sep; 9():85. PubMed ID: 18793415
[TBL] [Abstract][Full Text] [Related]
6. Cerebral ischemia induces microvascular pro-inflammatory cytokine expression via the MEK/ERK pathway.
Maddahi A; Edvinsson L
J Neuroinflammation; 2010 Feb; 7():14. PubMed ID: 20187933
[TBL] [Abstract][Full Text] [Related]
7. Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells.
Yip-Schneider MT; Klein PJ; Wentz SC; Zeni A; Menze A; Schmidt CM
J Pharmacol Exp Ther; 2009 Jun; 329(3):1063-70. PubMed ID: 19258520
[TBL] [Abstract][Full Text] [Related]
8. Circadian and photic regulation of phosphorylation of ERK1/2 and Elk-1 in the suprachiasmatic nuclei of the Syrian hamster.
Coogan AN; Piggins HD
J Neurosci; 2003 Apr; 23(7):3085-93. PubMed ID: 12684495
[TBL] [Abstract][Full Text] [Related]
9. Aryl hydrocarbon receptor activation and cytochrome P450 1A induction by the mitogen-activated protein kinase inhibitor U0126 in hepatocytes.
Andrieux L; Langouët S; Fautrel A; Ezan F; Krauser JA; Savouret JF; Guengerich FP; Baffet G; Guillouzo A
Mol Pharmacol; 2004 Apr; 65(4):934-43. PubMed ID: 15044623
[TBL] [Abstract][Full Text] [Related]
10. Prolonged extracellular signal-regulated kinase 1/2 activation during fibroblast growth factor 1- or heregulin beta1-induced antiestrogen-resistant growth of breast cancer cells is resistant to mitogen-activated protein/extracellular regulated kinase kinase inhibitors.
Thottassery JV; Sun Y; Westbrook L; Rentz SS; Manuvakhova M; Qu Z; Samuel S; Upshaw R; Cunningham A; Kern FG
Cancer Res; 2004 Jul; 64(13):4637-47. PubMed ID: 15231676
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of the MEK/ERK pathway reduces microglial activation and interleukin-1-beta expression in spinal cord ischemia/reperfusion injury in rats.
Lu K; Cho CL; Liang CL; Chen SD; Liliang PC; Wang SY; Chen HJ
J Thorac Cardiovasc Surg; 2007 Apr; 133(4):934-41. PubMed ID: 17382630
[TBL] [Abstract][Full Text] [Related]
12. Differential sensitivity of chemoresistant neuroblastoma subtypes to MAPK-targeted treatment correlates with ERK, p53 expression, and signaling response to U0126.
Eppstein AC; Sandoval JA; Klein PJ; Woodruff HA; Grosfeld JL; Hickey RJ; Malkas LH; Schmidt CM
J Pediatr Surg; 2006 Jan; 41(1):252-9. PubMed ID: 16410143
[TBL] [Abstract][Full Text] [Related]
13. MEK-inhibitor U0126 in hyperglycaemic focal ischaemic brain injury in the rat.
Farrokhnia N; Ericsson A; Terént A; Lennmyr F
Eur J Clin Invest; 2008 Sep; 38(9):679-85. PubMed ID: 18837745
[TBL] [Abstract][Full Text] [Related]
14. MEK inhibition of pancreatic carcinoma cells by U0126 and its effect in combination with sulindac.
Yip-Schneider MT; Schmidt CM
Pancreas; 2003 Nov; 27(4):337-44. PubMed ID: 14576498
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of the phosphodiesterase 4 (PDE4) enzyme reverses memory deficits produced by infusion of the MEK inhibitor U0126 into the CA1 subregion of the rat hippocampus.
Zhang HT; Zhao Y; Huang Y; Dorairaj NR; Chandler LJ; O'Donnell JM
Neuropsychopharmacology; 2004 Aug; 29(8):1432-9. PubMed ID: 15114341
[TBL] [Abstract][Full Text] [Related]
16. Identification of a novel inhibitor of mitogen-activated protein kinase kinase.
Favata MF; Horiuchi KY; Manos EJ; Daulerio AJ; Stradley DA; Feeser WS; Van Dyk DE; Pitts WJ; Earl RA; Hobbs F; Copeland RA; Magolda RL; Scherle PA; Trzaskos JM
J Biol Chem; 1998 Jul; 273(29):18623-32. PubMed ID: 9660836
[TBL] [Abstract][Full Text] [Related]
17. MEK1/2 inhibition attenuates vascular ETA and ETB receptor alterations after cerebral ischaemia.
Henriksson M; Stenman E; Vikman P; Edvinsson L
Exp Brain Res; 2007 Apr; 178(4):470-6. PubMed ID: 17091294
[TBL] [Abstract][Full Text] [Related]
18. Blockade of the extracellular signal-regulated kinase pathway by U0126 attenuates neuronal damage following circulatory arrest.
Cho DG; Mulloy MR; Chang PA; Johnson MD; Aharon AS; Robison TA; Buckles TL; Byrne DW; Drinkwater DC
J Thorac Cardiovasc Surg; 2004 Apr; 127(4):1033-40. PubMed ID: 15052200
[TBL] [Abstract][Full Text] [Related]
19. Selective potentiation of paclitaxel (taxol)-induced cell death by mitogen-activated protein kinase kinase inhibition in human cancer cell lines.
McDaid HM; Horwitz SB
Mol Pharmacol; 2001 Aug; 60(2):290-301. PubMed ID: 11455016
[TBL] [Abstract][Full Text] [Related]
20. Early modifications in the expression of mitogen-activated protein kinase (MAPK/ERK), stress-activated kinases SAPK/JNK and p38, and their phosphorylated substrates following focal cerebral ischemia.
Ferrer I; Friguls B; Dalfó E; Planas AM
Acta Neuropathol; 2003 May; 105(5):425-37. PubMed ID: 12677442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
